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Available online 4 December 2016Recent studies have reported an association between psychopathology and subsequent clinical and functional
outcomes in people at ultra-high risk (UHR) for psychosis. This has led to the suggestion that psychopathological
information could be used tomake prognostic predictions in this population. However, because the current liter-
ature is based on inferences at group level, the translational value of the ﬁndings for everyday clinical practice is
unclear. Here we examined whether psychopathological information could be used to make individualized pre-
dictions about clinical and functional outcomes inpeople atUHR. Participants included 416 people atUHR follow-
ed prospectively at the Personal Assessment and Crisis Evaluation (PACE) Clinic inMelbourne, Australia. The data
were analysed using Support Vector Machine (SVM), a supervisedmachine learning technique that allows infer-
ences at the individual level. SVM predicted transition to psychosis with a speciﬁcity of 60.6%, a sensitivity of
68.6% and an accuracy of 64.6% (p b 0.001). In addition, SVM predicted functioning with a speciﬁcity of 62.5%,
a sensitivity of 62.5% and an accuracy of 62.5% (p= 0.008). Prediction of transition was driven by disorder of
thought content, attenuated positive symptoms and functioning, whereas functioning was best predicted by at-
tention disturbances, anhedonia–asociality and disorder of thought content. These results indicate that psycho-
pathological information allows individualized prognostic predictions with statistically signiﬁcant accuracy.
However, this level of accuracy may not be sufﬁcient for clinical translation in real-world clinical practice. Accu-
racymight be improved by combining psychopathological informationwith other types of data using amultivar-
iate machine learning framework.Studies, I
n SE5 8A
. This is© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Support vector machine1. Introduction
The onset of a psychotic disorder is typically preceded by a prodro-
mal phase, known as the ultra high risk (UHR) state, involving the emer-
gence of attenuated positive symptoms and a marked decline in
functioning (Fusar-Poli et al., 2013; Yung et al., 1996). With the increas-
ing appreciation of the clinical beneﬁts of early intervention inpsychosis
(McGorry et al., 2008), a number of pharmacological and psychological
treatments are being employed to delay or prevent the onset of thenstitute of Psychiatry,
F, UK
an open access article underillness in people at UHR (Mechelli et al., 2015). Because approximately
two-thirds of peoplewhomeet criteria for UHRwill not develop the dis-
order, treatment that is intended to be preventativemay be provided to
individualswhomay not actually need it. Therefore, the development of
predictive tools, that could be used to tailor clinical intervention to the
level of risk amongst people at UHR, has become a major translational
goal for psychiatric research (Nelson and Yung, 2010).
An association between psychopathology and subsequent clinical
outcome in people at UHR for psychosis has been found in a number
of studies. The most consistent ﬁnding is a positive correlation between
severity of bizarre thinking/unusual thought content and risk of transi-
tion to psychosis which has been observed in four independent samples
(Cannon et al., 2008; Thompson et al., 2011; Velthorst et al., 2009;
Ziermans et al., 2014). Other aspects of psychopathology found to bethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ence of brief limited intermitted psychotic symptoms (Nelson et al.,
2011), severity of positive symptoms (Ziermans et al., 2014), elevated
mood (Thompson et al., 2013), severity of delusions (Thompson et al.,
2013), basic self-disturbance (Nelson et al., 2012) and disorganised
communication (Addington et al., 2015). In addition, disorganised
symptoms (Carrion et al., 2013; Ziermans et al., 2014) and negative
symptoms (Lin et al., 2011; Meyer et al., 2014) have been found to be
predictive of functional outcomes irrespective of transition to psychosis.
Collectively, theseﬁndings indicate that itmay be possible to use careful
clinical assessment to predict transition to psychosis as well as psycho-
social functioning in individuals at UHR for psychosis.
A critical limitation of the above literature, however, is that the stud-
ies published so far typically reported effects that were statistically sig-
niﬁcant at the group level, whereas clinicians have to make treatment
decisions about individual patients. Because effects that are statistically
signiﬁcant at a group level do not necessarily permit accurate inferences
at the level of the individual, the translational potential of the ﬁndings
for everyday clinical practice is unclear. One way of addressing this lim-
itation is to employ supervised machine learning techniques, such as
support vector machine (SVM), which permit statistical inferences at
the level of the individual and as such have high translational potential
in clinical practice (Orru et al., 2012).
While several studies have applied supervised machine learning
techniques to neuroimaging and neurocognitive data to predict clinical
and functional outcomes in people at UHR for psychosis (Kim et al.,
2011; Koutsouleris et al., 2012a, 2012b, 2009; Simon et al., 2012;
Tognin et al., 2013), to our knowledge no previous investigation has
employed this approach to examine the prognostic value of clinical in-
formation. The aim of the present study was therefore to examine
whether clinical information acquired at baseline could be used to
make individualized predictions about long-term clinical and functional
outcomes in people at UHR for psychosis. We used longitudinal data
from service users at the Personal Assessment and Crisis Evaluation
(PACE) clinic, Orygen Youth Health. Participants received a detailed
psychopathological assessment at ﬁrst clinical presentation and were
followed-up at regular intervals for an average period of 7.5 years; full
details of the protocol can be found in Nelson et al. (2013) (Nelson et
al., 2013). Based on the existing literature that used group-level statis-
tics (Cannon et al., 2008; Carrion et al., 2013; Meyer et al., 2014;
Nelson et al., 2013, 2011; Thompson et al., 2013, 2011; Velthorst et al.,
2009; Ziermans et al., 2014), we tested two related hypotheses. First,
psychopathological measures including a combination of positive and
negative symptoms and functioning variables would allow individual-
ized prediction of transition to psychosiswith statistically signiﬁcant ac-
curacy; more speciﬁcally, we expected prediction to be driven by the
presence of disorder of thought content, intensity of attenuated positive
symptoms and poor functioning (Cannon et al., 2008; Nelson et al.,
2013; Thompson et al., 2011; Velthorst et al., 2009; Ziermans et al.,
2014). Second, psychopathological measures would also allow individ-
ualizedprediction of functional outcomewith statistically signiﬁcant ac-
curacy; in this case we expected prediction to be mainly informed by
disorganised (Carrion et al., 2013; Ziermans et al., 2014) and negative
(Meyer et al., 2014; Nelson et al., 2013) symptoms.
2. Materials and methods
2.1. Setting and sample
The PACE clinic is a specialist clinic for people at UHR for psychosis.
The catchment area of the service includes northwestern metropolitan
Melbourne, Australia. Young people between the age of 15 and 30 are
accepted into PACE if they meet criteria for at least one of three UHR
groups: (i) attenuated psychotic symptoms (APS), (ii) brief limited in-
termitted psychotic symptoms (BLIPS), and (iii) trait risk factor (Trait)
(Yung et al., 2003). Exclusion criteria for the PACE clinic are thepresence of a current or past psychotic disorder, known organic cause
for presentation, and past neuroleptic exposure equivalent to a total
continuous haloperidol dose of N15 mg (which may modify risk of
transition).
A total of 416 people (200 males, 216 female) who met criteria for
UHR for psychosis were included in the present investigation (mean
age = 19.38, SD = 3.35). All were recruited between 1993 and 2006
and followed up for an average of 7.5 years (median: 8.04, range: 2.4–
14.9). Within the sample, 114 individuals (27%) had made transition
to psychosis during the follow-up period whereas the remaining 302
(73%) had not. The demographic and clinical characteristics of this sam-
ple have been reported and discussed in detail in a previous publication
(Nelson et al., 2013). The study was approved by the local ethics
committee and written informed consent was obtained from all
participants.
2.2. Baseline measures
A range of clinical measures acquired at baseline were used to
predict clinical and functional outcomes including the Brief Psychiatric
Rating Scale (BPRS); the Scale for Assessment of Negative Symptoms,
(SANS); the Comprehensive Assessment of At Risk Mental State
(Yung et al., 2005) (CAARMS); and the Global Assessment of Func-
tioning (GAF). See Fig. 1 and Supplementary data for list of speciﬁc
subscales.
2.3. Outcome measures
The main outcome measure of interest was transition to psychotic
disorder. This was deﬁned as at least one fully positive psychotic symp-
tom several times a week for more than one week using both the BPRS
and the CAARMS (Yung et al., 2004). A further outcome measure of in-
terest was level of functioning at last follow-up. This was assessed using
the Social and Occupational Functioning Assessment Scale (SOFAS),
with a follow-up score N 50 indicating good functioning and a follow-
up score ≤ 50 indicating poor functioning; this cut-off was chosen as it
is often used to distinguish between poor and good functioning in clin-
ical practice.
2.4. Support vector machine
The data were analysed using SVM as implemented in PROBID
software (http://www.kcl.ac.uk/ioppn/depts/neuroimaging/research/
imaginganalysis/Software/PROBID.aspx). SVM is a multivariate ma-
chine learning technique that allows the classiﬁcation of individual ob-
servations into distinct groups using the rules of probability (see
Supplementary Data for more detail) (Vapnik, 1999). SVM comprises
a “training” phase, in which well characterized training data are used
to develop an algorithm which captures the key differences between
groups, and a “testing” phase, in which the algorithm is used to predict
the group that a new observation belongs to (Orru et al., 2012). For the
purpose of the present investigation, a predictive algorithm was de-
veloped using a radial basis function kernel and leave-one-out cross-
validation. This involved: (i) excluding a single subject from each
group; (ii) training the classiﬁer using the remaining subjects; (iii)
using the subject pair excluded to test the ability of the classiﬁer to
reliably distinguish between groups; and (iv) repeating this proce-
dure for each subject pair in order to assess the generalizability of
the classiﬁer in terms of accuracy, sensitivity and speciﬁcity. The sta-
tistical signiﬁcance of the accuracy was determined by permutation
testing; this involved repeating the classiﬁcation procedure with a
different random permutation of the training group labels 1000
times, and dividing the number of permutations achieving higher
sensitivity and speciﬁcity than the true labels by the total number
of permutations.
Fig. 1. Relative contributions of clinical measures to prediction of long-term clinical outcome (i.e. converters versus non-converters). A positive weight value indicates that a measure
contains valuable information for identifying converters, whereas a negative value indicates that it contains valuable information for identifying non-converters.
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questions. Firstly, can clinical data predict subsequent transition to psy-
chosis at the individual level (i.e. transition versus non-transition)? Sec-
ondly, can clinical data predict subsequent level of functioning at the
individual level (i.e. poor versus good functioning)? Ideally, the use of
SVM to compare two groups of interest requires them to have the
same sample size; furthermore, to maximize the external validity of
the ﬁndings, participants in the two groups should be matched on
basic demographic variables, i.e. age and gender (Orru et al., 2012). In
order to address theﬁrst question,we therefore selected 99 transitioned
participants and 99 non-transitioned participants individually matched
for gender and age (±2 years); the demographic and clinical character-
istics of these two groups are reported in Table 1. In order to address the
second question, we selected 48 participants with a follow-up SOFAS
score N 50, who were classiﬁed as high functioning, and 48 participants
with a follow-up SOFAS score ≤ 50, whowere classiﬁed as low function-
ing, individually matched for gender and age (±2 years); the demo-
graphic and clinical characteristics of these groups are also reported in
Table 1. In addition, because functioning can also be thought of as a
continuous variable, we carried out a further machine learning analysis
of high- and low- functioning participants using an alternative version
of SVM known as Support Vector Regression (SVR) (Smola and
Scholkopf, 2004). The advantage of SVR, relative to SVM, is that it allows
the quantitative prediction of a variable of interest (e.g. a patient's score
on a scale of interest) without the need for a discrete categorical deci-
sion (e.g. low vs. high functioning). SVR was implemented in Scikit-
learn (http://scikit-learn.org/stable/) using a radial basis function
kernel and a nested cross-validation design. The inner 10-fold loop
optimised the values of the parameters to be estimated (C, epsilon
and gamma), while the outer 10-fold loop tested these parameters
in subjects not used in training. This was repeated 100 times with
random shufﬂing of the data to produce a variety of different train/
test splits, and all the ﬁnal sets of predictions were then averaged.
The statistical signiﬁcance of this ﬁnal set of prediction was estimat-
ed using a permutation test whereby the actual and predicted scores
were randomly paired 1000 times and a new SVR was run for each
random pairing. Statistical inferences were made at p b 0.05 with
Bonferroni correction for multiple comparisons to account for thenumber of outcome measures investigate (i.e. transition and func-
tioning); this resulted in an actual p-value of p b 0.025 for each statis-
tical comparison.
3. Results
3.1. Prediction of transition to psychosis
SVMwas able to discriminate between individuals at UHRwho sub-
sequently did and did not make transition to psychosis with speciﬁcity
of 60.6%, a sensitivity of 68.6% and an accuracy of 64.6%; permutation
testing indicated that this was statistically signiﬁcant (p b 0.001).
The relative contributions of the different symptoms to prediction of
transition to psychosis are displayed in Fig. 1. Here a positive weight
means that the measure in question contained valuable information
for identifying individuals who made transition, whereas a negative
weight means that it was useful for identifying individuals who did
not make transition. Individualized predictions were mainly driven by
three measures. The ﬁrst of these measures was disorder of thought
content as indexed by the CAARMS, which was higher in the transition
than the non-transition group (p b 0.001; see Table 1) and added to the
prediction of those individuals who made transition. The second mea-
sure was intensity of attenuated positive symptoms as indexed by the
psychotic subscale of the BPRS, which was higher in the transition
than the non-transition group (p = 0.001; see Table 1) and added to
the prediction of those individuals whomade transition. The thirdmea-
sure was functioning as indexed by the GAF, which was higher in the
non-transition than the transition group (p b 0.001; see Table 1) and
added to the prediction of those individuals who did not make
transition.
3.2. Prediction of functioning
SVM was able to discriminate between the two subgroups with a
speciﬁcity of 62.5%, a sensitivity of 62.5% and an accuracy of 62.5%; per-
mutation testing indicated that this was statistically signiﬁcant (p =
0.008). Consistent with this ﬁnding, the use of SVR allowed quantitative
Table 1
Demographic and clinical characteristics of participants. The participants used for the analysis of functioning were a subset of the participants used for the analysis of transition. Values
denote mean with standard error in brackets. n= number of subjects in each group; UHR-T = individuals at ultra-high risk who made transition to psychosis; UHR-T = individuals at
ultra-high risk who did not make transition to psychosis; Poor= individuals who showed a SOFAS score ≤ 50 at follow-up indicating poor functioning; Good= individuals who showed
a SOFAS score N 50 at follow-up indicating good functioning. The asterisk (*) indicates that this informationwas available for 75/98 individualswhomade transition and 77/98who did not
make transition to psychosis.
Prediction of transition Prediction of functioning
UHR-T
(n = 99)
UHR-NT
(n = 99)
Comparison Low
(n = 48)
High
(n = 48)
Comparison
Age 19.52 (3.62) 19.40
(3.37)
t = 0.223
df = 196
p = 0.824
19.71 (3.06) 19.65 (3.62) t = 0.091
df = 94
p = 0.928
Gender (male/female) 48/51 48/51 ×2 b 0.001
df = 1
p = 1
22/26 22/26 ×2 b 0.001
df = 1
p = 1
Time between baseline assessment and follow-up (days) 3203.19
(1020.341)
2965.79
(1194.932)
t = 1.316⁎
df = 150
p = 0.190
2833.44
(1262.114)
2630.33
(1061.003)
t = 0.853
df = 94
p = 0.396
Psychotic subscale (BPRS) 10.11 (3.2) 8.63 (2.67) t = 3.54
df = 196
p = 0.001
10.29 (3.3) 9.69 (2.86) t = 0.959
df = 94
p = 0.340
Alogia (SANS) 2.57 (2.85) 1.99 (2.38) t = 1.54
df = 196
p = 0.125
3.44 (3.16) 2.13 (1.86) t = 2.474
df = 94
p = 0.015
Avolition (SANS) 4.57 (3.36) 3.65 (2.88) t = 2.065
df = 196
p = 0.040
4.92 (3.29) 3.90 (3.18) t = 1.544
df = 94
p = 0.126
Anhedonia–Asociality (SANS) 6.78 (4.92) 5.44 (4.65) t = 1.956
df = 196
p = 0.052
7.65 (5.15) 5.19 (3.78) t = 2.662
df = 94
p = 0.009
Attention (SANS) 2.03 (2.17) 1.28 (1.8) t = 2.631
df = 196
p = 0.090
2.48 (2.35) 0.96 (1.28) t = 3.930
df = 94
p b 0.001
GAF 54.54 (11.31) 61.10 (11.81) t = −3995
df = 196
p b 0.001
55.27 (11.2) 58.96 (9.51) t = −1.738
df = 94
p = 0.085
Disorder of thought content
(CAARMS)
2.29 (0.95) 1.66 (1.05) t = 4.468
df = 196
p b 0.001
2.19 (0.86) 1.85 (1.03) t = 1.714
df = 94
p = 0.091
Perceptual abnormalities
(CAARMS)
2.45 (1.45) 2.11 (1.44) t = 1.662
df = 196
p = 0.098
2.42 (1.36) 2.40 (1.55) t = 0.070
df = 94
p = 0.945
Conceptual disorganisation
(CAARMS)
2.04 (1.02) 1.73 (1.15) t = 2.019
df = 196
p = 0.045
2.00 (1.05) 1.69 (1.05) t = 1.453
df = 94
p = 0.149
Motor disturbances
(CAARMS)
0.75 (1.06) 0.61 (1.01) t = 0.956
df = 196
p = 0.340
0.69 (1.03) 0.67 (1.07) t = 0.097
df = 94
p = 0.923
Disorder of concentration, attention and memory
(CAARMS)
2.18 (1.19) 1.92 (1.14) t = 1.58
df = 196
p = 0.116
2.21 (1.23) 2.23 (0.973) t = −0.092
df = 94
p = 0.927
Disorder of emotion and affect
(CAARMS)
1.82 (1.32) 1.54 (1.28) t = 1.521
df = 196
p = 0.130
2.04 (1.32) 1.83 (1.13) t = 0.829
df = 94
p = 0.409
Impaired energy
(CAARMS)
1.92 (1.18) 1.90 (1.12) t = 0.123
df = 196
p = 0.902
1.83 (1.13) 1.97 (1.02) t = −0.662
df = 94
p = 0.510
Impaired tolerance to normal stress
(CAARMS)
1.95 (1.25) 1.79 (1.18) t = 0.93
df = 196
p = 0.354
1.90 (1.20) 2.00 (1.07) t = −0.447
df = 94
p = 0.656
Impaired bodily sensation
(CAARMS)
0.96 (1.25) 0.70 (1.06) t = 1.59
df = 196
p = 0.113
0.60 (1.10) 1.04 (1.12) t = −1.918
df = 94
p = 0.058
Impaired autonomic functioning
(CAARMS)
1.04 (1.25) 0.84 (1.13) t = 1.191
df = 196
p = 0.235
1.21 (1.23) 1.21 (1.23) t b 0.001
df = 94
p = 1.000
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correlation r= 0.275, p= 0.009; mean squared-error = 376).
The relative contributions of the different symptoms to prediction of
functional outcome are displayed in Fig. 2. Here a positiveweightmeans
that the measure in question contained valuable information for identi-
fying individuals whowere low functioning, whereas a negative weight
means that itwas useful for identifying individualswhowere high func-
tioning. It can be seen that individualized predictions were driven byseveral measures, such as attention disturbances as measured by the
SANS, which were more pronounced in the low- than the high-func-
tioning group (p b 0.001; see Table 1); anhedonia–asociality as mea-
sured by the SANS, which was more pronounced in the low- than the
high-functioning group (p = 0.009; see Table 1); and disorder of
thought content as measured by the CAARMS, which did not differ be-
tween high- and low-functioning groups based on group-level statistics
(p = 0.091; see Table 1). All three measures were associated with
Fig. 2. Relative contributions of clinical measures to prediction of long-term functional outcome (i.e. poor versus good functioning). A positive weight value indicates that a measure
contains valuable information for identifying low-functioning individuals, whereas a negative value indicates that it contains valuable information for identifying high-functioning
individuals.
36 A. Mechelli et al. / Schizophrenia Research 184 (2017) 32–38positive weight values (see Fig. 2), indicating that they contained valu-
able information for identifying low-functioning individuals.
4. Discussion
Previous studies had shown an association between psychopatholo-
gy and subsequent clinical or functional outcome in people at UHR for
psychosis (Cannon et al., 2008; Nelson et al., 2013; Thompson et al.,
2011; Velthorst et al., 2009; Yung et al., 2015; Ziermans et al., 2014).
However, effects that are statistically signiﬁcant at a group level do not
necessarily permit accurate inferences at the level of the individual.
The results of the present investigation expands the existing literature
by showing that psychopathologicalmeasures allow individualized pre-
dictions in people at UHR for psychosis. Speciﬁcally, we found that a
combination of clinical data acquired using the BPRS, SANS, CAARMS
and GAF predicted transition to psychosis and functioning with above-
chance accuracies of 64.6% and 62.5% respectively. In addition, the use
of a parametric approach allowed quantitative prediction of functioning
with statistically signiﬁcant accuracy (p= 0.007).
We note that statistically signiﬁcant accuracy does not necessarily
imply clinical utility in real-world clinical practice. The clinical utility
of a prognostic test depends on several aspects such as the ability to
generate a “divergent prediction” and the availability of alternative in-
terventions (Mechelli et al., 2015; Perlis, 2011). For example, a test
that is accurate at predicting a given outcome of interest may not be
particularly useful if that outcome is only observed in a very small frac-
tion of thepatient population,while a test that is accurate at predicting a
highly heterogeneous clinical outcome could be of clinical value. In the
context of individuals at UHR for psychosis, the ability to predict transi-
tionwith an accuracy of 64.6%may be of little clinical value if the risk of
transition to psychosis is small (Fusar-Poli et al., 2012; Yung et al.,
2007). The eventual development of tools for tailoring intervention to
the level of risk in this clinical population, therefore, will ultimately re-
quire greater levels of accuracy, sensitivity and speciﬁcity than those
found in the present investigation.
Recent studies (Addington et al., 2015; Cannon et al., 2008; Cotter et
al., 2014; Lencz et al., 2006;Michel et al., 2014;Nieman et al., 2014) sug-
gest that greater levels of accuracy, sensitivity and speciﬁcity could be
achieved through the integration of psychopathological measures with
other types of data. For example, it is possible to reﬁne prediction of
transition to psychosis by combined psychopathological informationwith measures of genetic risk (Thompson et al., 2013), years of educa-
tion (Ruhrmann et al., 2010), substance abuse (Thompson et al.,
2013), sleep disturbances (Ruhrmann et al., 2010), premorbid adjust-
ment (Nieman et al., 2014), cognitive impairment (Lencz et al., 2006;
Michel et al., 2014; Riecher-Rossler et al., 2009) and neurophysiology
(Nieman et al., 2014). It should be noted, however, that in these studies
prediction was typically based on the development of a single cut-off
score that was estimated at group rather than individual level. In addi-
tion, none of these studies examined the generalizability of the predic-
tive model using a cross-validation procedure that employed separate
training and testing data. Future studies could use multivariate super-
vised machine learning techniques to integrate different types of data,
with the aim of improving on the levels of accuracy, sensitivity and
speciﬁcity that were observed in the present investigation.
Interestingly, individualized prediction of transition to psychosis
wasmainly driven by disorder of thought content, intensity of attenuat-
ed positive symptoms and functioning. This aspect of our results is con-
sistent with previous studies (Addington et al., 2015; Carrion et al.,
2013; Nelson et al., 2012, 2013; Thompson et al., 2013) and emphasizes
the importance of considering functioning in the clinical management
of people at UHR for psychosis (Cotter et al., 2014). In addition, the ob-
servation that disorder of thought content, intensity of attenuated psy-
chotic symptoms and functioning made independent contributions to
prediction, suggests that these three aspects reﬂect independent rather
than overlapping processes along the pathway to psychosis. In contrast,
long-term functional outcomewasmainly informed by attention distur-
bances, anhedonia–asociality and disorder of thought content. There-
fore, functional outcome depends on a diverse collection of features
that are overlapping with but distinct from those inﬂuencing transition
to psychosis.
We note that the levels of accuracy, sensitivity and speciﬁcity in the
present investigation were lower than in those found in similar studies
that have employed neuroimaging data (McGuire et al., 2015). For ex-
ample, using structural Magnetic Resonance Imaging (MRI) data,
Koutsouleris et al. (2015) developed an algorithm that predicted transi-
tion to psychosis with an accuracy of 80.4%, a sensitivity of 75.8% and a
speciﬁcity of 85.0%. In addition, usingMRI data, the same research group
was able to predict functional outcomewith an accuracy of 81.6%, a sen-
sitivity of 78.6% and a speciﬁcity of 84.6% (Kambeitz-Ilankovic et al.,
2015). A possible explanation is that psychopathological measures are
less directly related to the pathophysiological processes that underlie
37A. Mechelli et al. / Schizophrenia Research 184 (2017) 32–38transition to psychosis than neuroimaging data. Another potential expla-
nation is that the present investigation focused on prediction of long-
term outcomes (i.e. 7.5 years on average), whereas studies that employed
neuroimaging data usedmuch shorter follow-ups (i.e. up to 2 years). Nev-
ertheless, there are several advantages associated with the use of psycho-
pathological measures in everyday psychiatric practice. First, clinical tests
are available to psychiatric services in developed as well as developing
countries; in contrast, neuroimaging is still only available to a small frac-
tion of the 1.5 million people in the world who develop schizophrenia
each year. Second, clinical tests are relatively easy to administer and inter-
pret; while the neuroanatomical alterations associated with transition to
psychosis can only be detected after a series of analytical steps that require
technical expertise and computational resources beyond the capabilities
of most clinical units. Third, most clinical tests can be scored within a
short time allowing clinicians to make prompt treatment decisions; in
contrast, the statistical analysis of neuroimaging data can take hours or
days to complete. It would be impractical and potentially harmful to the
patient to delay a treatment decision until the results of such analysis be-
come available. In light of these advantages, psychopathology could be
used to inform the clinicalmanagement of people at UHRuntil other tech-
niques such as neuroimaging become widely available.
The present investigation has several strengths. In particular, (i) the
application of SVM to the data allowed us to make statistical inferences
at the level of the individual rather than the group; (ii) the sample size
was considerably larger than in any previous study using supervised
machine learning techniques to predict outcomes in the UHR popula-
tion; (iii) participants in different sub-groups (i.e. transition versus
non-transition; poor versus good functioning) were individually
matched for age and gender; and (iv) outcome was assessed not only
in terms of transition to psychosis but also in terms of functioning.
The present investigation also has important limitations. Firstly, we fo-
cused on the predictive value of clinical and functional information
without considering other types of data that might improve prognostic
accuracy. Secondly, most participants received psychosocial and/or
pharmacological treatment over the follow-up period; this raises the
possibility that our ﬁndings might reﬂect individual differences in re-
sponse to treatment rather than putative prognostic risk. We note that
this limitation is not speciﬁc to the present investigation but applies
to most, if not all, studies of people at UHR for psychosis. Thirdly,
there were minor modiﬁcations to the UHR criteria and instruments
used to assess these over the recruitment period although there is no
reason to expect that this had signiﬁcant effects (Nelson et al., 2013).
Fourthly, the high degree of variability in follow-up time (see
Materials and methods for detail) may have introduced noise to the
data, resulting in an under-estimation of predictive accuracies.
In conclusion, our ﬁndings demonstrate that psychopathological fea-
tures allow individualized prognostic predictions in people at UHR for
psychosis with statistically signiﬁcant accuracy. However, we argue that
the eventual development of prognostic tools for predicting risk and tai-
loring intervention in this clinical population, will ultimately require
greater levels of accuracy, sensitivity and speciﬁcity than those reported
in the present study. This could be achieved by combining psychopatho-
logical information with other types of data using a multivariate super-
vised machine learning framework (Pettersson-Yeo et al., 2014).
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